Comparison of the efficacy and safety of Latanoprost 0.005% (XalatanÂ® Reference) and Latanoprost 0.005% (Sun Pharma Advanced Research Company Ltd) administered once daily in open angle glaucoma and ocular hypertension.

Sun Pharma Advanced Research Company Ltd0 个研究点目标入组 100 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Men and women aged 18 years and above.
•Unmedicated IOP equal to or greater than 22 mmHg in one or both eyes
•Visual acuity 6/60 or better
•Willingness to participate and giving written informed consent
•Willing to commit to study medication-dosing, study visits and follow-up visits to complete evaluation

•Pigmentary glaucoma
•Intraocular conventional surgery or laser surgery within the past six months
•Refractive surgery in study eye
•Angle closure glaucoma or a history of acute angle closure treated with a peripheral iridotomy
•Ocular trauma within the past 3 months
•Progressive retinal or optic nerve disease apart from glaucoma
•Concurrent infectious/non infectious conjunctivitis, keratitis, or uveitis in either eye
•Contact lens wear within 15 minutes of instillation of study medication
•Women of childbearing potential who have positive serum pregnancy test or are lactating or not using adequate contraception
•Clinically significant systemic disease, which might interfere with the study
•History of non-compliance to medical regimens or unwilling to comply with the study protocol
•Participation in another clinical study within the last thirty (30) days
•Changes in systemic medication within 30 days prior to screening that could have a substantial impact on IOP, or anticipated changes during the study
•Refusal or inability to give written informed consent

发起方